Global pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its new injectable facility located in Nagpur, India. The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022.
